S
MRTX

SignatureFD’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

SignatureFD’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,021
Closed -$60K – 3292
2023
Q4 		$60K Buy
1,021
+444
+77% +$25K ﹤0.01% 1375
2023
Q3 		$25.1K Buy
577
+277
+92% +$9.89K ﹤0.01% 1739
2023
Q2 		$10.8K Buy
300
+64
+27% +$2.64K ﹤0.01% 2199
2023
Q1 		$8.77K Sell
236
-309
-57% -$13.9K ﹤0.01% 2274
2022
Q4 		$24.7K Sell
545
-804
-60% -$52K ﹤0.01% 1700
2022
Q3 		$94K Buy
1,349
+36
+3% +$2.66K ﹤0.01% 985
2022
Q2 		$88K Buy
1,313
+975
+288% +$62K ﹤0.01% 1040
2022
Q1 		$28K Buy
338
+171
+102% +$17.5K ﹤0.01% 1678
2021
Q4 		$24K Buy
167
+140
+519% +$21.7K ﹤0.01% 1717
2021
Q3 		$5K Buy
27
+3
+13% +$483 ﹤0.01% 2390
2021
Q2 		$4K Buy
24
+6
+33% +$963 ﹤0.01% 2400
2021
Q1 		$3K Sell
18
-16
-47% -$3.17K ﹤0.01% 2404
2020
Q4 		$7K Buy
34
+20
+143% +$4.32K ﹤0.01% 1864
2020
Q3 		$2K Hold
14
– – ﹤0.01% 2308
2020
Q2 		$2K Buy
+14
New +$1.36K ﹤0.01% 2218

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SignatureFD's MRTX Position: Q1 2024 in Review

SignatureFD sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,021 shares — an estimated $60K sold.

SignatureFD first reported a position in MRTX in Q2 2020 and held it in 15 quarters. The position peaked at $94K in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • SignatureFD reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • SignatureFD sold 1,021 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $60K.
  • SignatureFD first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 15 quarters.
  • SignatureFD's Mirati Therapeutics, Inc. Common Stock position peaked at $94K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on SignatureFD's 13F filing for Q1 2024, filed 3 May 2024.